NCT03183505已完成2 期
Safety and Efficacy Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Ⅱb Stratified Randomized, Double-Blind, Placebo-Paralleled, Multicenter Clinical Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 172
- 试验地点
- 8
- 主要终点
- The change of total score from baseline in MADRS scale
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of Anyu Peibo Capsule comparing with placebo in the treatment of Chinese Patients with Depression. And to provide some scientific evidence for protocol designing in following phase Ⅲ clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria of DSM-5, single episode or recurrent episode.
- •The total score of MADRS is ≥24 in both screening visit and baseline visit.
- •The total score of HAMD-17 is ≥18 and the first item (depressed mood) is ≥2 in both screening visit and baseline visit.
- •CGI-S is ≥4 in both screening visit and baseline visit.
- •The subject understands and consents to takes part in this clinical trials. The subjects should sign informed consent form.
排除标准
- •The subject has a suicide attempt within recent 1 year, or has a currently significant risk of suicide, or has a score ≥3 on item 3(suicide assessment) of the HAMD.
- •The subject has a current psychiatric diagnosis other than depression.
- •When the HAMD-17 score of baseline visit compares with the screening visit, the decreasing rate is ≥25%.
- •Known hypersensitivity to Big Leaf Ju, or at least to two kinds of drugs.
- •Any unstable cardiovascular, hepatic, renal, blood, endocrine, or other medical disease.
- •Any neurological disease (such as Parkinson's Disease, cerebrovascular accident and epilepsy) or cerebral injury (traumatic or disease related).
- •Had a history or a high risk related disease or medication of seizure disorder,except infantile febrile convulsion.
- •Had a history of hyperthyroidism or hypothyroidism within recent 1 year and still taking medication.
- •With psychotic symptoms.
- •The subject has a history of mania episode, including manic, mixed, bipolar depression or rapid cycle attack.
- •The subject has a current diagnosis of depression due to a somatic disease.
- •The subject could not take medication or has a disease affecting drug absorption, such as active bowel disease, partial or total intestinal obstruction, or chronic diarrhea.
- •Clinically significant electrocardiographic(ECG) abnormalities in screening visit. Such as QTc ≥450 ms in male or ≥470 ms in female; Sinus bradycardia and HR ≤ 50 bpm; Ⅲ atrioventricular block; atrial fibrillation, etc.
- •Clinically significant abnormal laboratory values(eg. Routine blood value above or below 1.2 times of the normal range; urine WBC, RBC or protein ≥++; ALT or AST value above 1.5 times of clinical top-limit; BUN value above 1.2 times of top-limit; Cr value above normal top-limit; thyroid gland function index above or below 1.2 times of the normal range, Fasting plasma glucose value above 1.2 times of normal top-limit; blood fat value above 1.5 times of normal top-limit).
- •The subject who used at least two different antidepressants with recommended dose and adequate duration (maximum dosage by at least 4 weeks according to label) treatment still had no respond.
- •The subject uses antidepressant drug normally before 2 weeks of screening, and stops using psychotropic drug before randomization less than 7 half-life period (monoamine oxidase inhibitor: at least 2 weeks; fluoxetine: at least 1 month)
- •The subject received light therapy within 2 weeks.
- •The subject received ECT, trans-cranial magnetic stimulation, or other physics therapy within 3 months.
- •The subject received systematic psychotherapy (interpersonal relationship, psychoanalytic therapy, or cognitive behavioral therapy) within 3 months or plan to use systematic psychotherapy during the study period.
- •The subject has a history of substance abuse (including alcohol, drug or other psychoactive substance) within 1 year before screening.
- •Women who were pregnant, breast-feeding, or serum-HCG(+) on screening; or planning to become pregnant within 3 months after kick-off of clinical trial.
- •The subject has participated in a drug clinical trial within 1 month before screening.
- •The investigator thinks the subject is unsuitable to enroll in this clinical trial.
研究组 & 干预措施
Anyu Peibo
Experimental
Anyu Peibo Capsule, oral, 0.8g twice per day
干预措施: Anyu Peibo (Drug)
Placebo
Placebo Comparator
Placebo,oral, twice per day
干预措施: Placebo (Drug)
结局指标
主要结局
The change of total score from baseline in MADRS scale
时间窗: 6 weeks
次要结局
- Clinical Response Rate according to HAMD-17(6 weeks)
- Clinical Remission Rate according to HAMD-17(6 weeks)
- the Change of CGI (CGI-S, CGI-I) from baseline(6 weeks)
- Clinical Remission Rate according to MADRS(6 weeks)
- Clinical Response Rate according to MADRS(6 weeks)
- the Change of total score from baseline in HAMA(6 weeks)
研究者
研究点 (8)
Loading locations...
相似试验
Unknown
3 期
Comparison of Anyu Peibo With Placebo in Treatment of MDD in ChinaMajor Depressive DisorderNCT04210973Shanghai Mental Health Center266
已完成
2 期
Comparison of Anyu Peibo With Placebo in Treatment of MDDMajor Depressive Disorder (MDD)NCT02380066Shanghai Mental Health Center120
已完成
2 期
Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney DiseaseDiabetic Kidney DiseaseType 2 Diabetes MellitusNCT03164785Second Xiangya Hospital of Central South University202
招募中
2 期
Clinical study of Beone Capsule in healthy individualsCTRI/2023/03/050313upin Ltd
尚未招募
3 期
A clinical trial to evaluate the medicinal efficacy of Ayurvedic Tablet Bhoumya and Tablet Saathmya in COVID-19 positive Patients.CTRI/2020/06/025671Dr Giridhara Kaje